- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
International Journal of Proteomics
Volume 2012 (2012), Article ID 641491, 2 pages
1Clinical Protein Science and Imaging, Lund University, 221 84 Lund, Sweden
2Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan
3Department of Chemistry and Biology, Ryerson University, Toronto, ON, Canada M5B 2K3
Received 1 August 2012; Accepted 1 August 2012
Copyright © 2012 Ákos Végvári et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In a rapidly developing technological environment, including advances of mass spectrometric platforms, proteomic applications gain ever-increasing attentions in particularly linked to diseases, offering new means to improve the state-of-the-art in diagnosis and therapy . However, clinical proteomics should not be considered as a collection of studies dealing with analyses of clinical samples but rather studies that can raise clinically relevant questions. As such, clinical proteomics systematically employs proteomic technologies, laboratory medicine, bioinformatics in order to identify protein patterns of diseases comprehensively that can lead to improved patient care and public health for the benefit of better assessment of prevention of disease, detection and diagnosis of disease, selection of personalized therapy, and monitoring of treatment response.
In this Special Issue, we present a small set of research and review articles contributing to the field of clinical proteomics. Today, biomarker discovery is certainly one of the most important and widely investigated areas. Although, current routine analyses in clinical chemistry include more than 200 proteins being analyzed in blood samples and an addition number of protein markers that are used for flow cytometry and antigens, none of these biomarkers have been originating from proteomics . Furthermore, quantification of proteins with clinical importance is largely performed by immunoreaction-based assays (e.g., ELISA), where the available methodologies are numerous. However, modern mass spectrometry developments have already brought sufficient power, which are complementary to or even competitors of immunoreaction-based technologies in biomarker research .
The essential advantage of the proteomic approach is the potential to identify and quantify multiple biomarkers simultaneously in the large parts of the human proteome, providing an overall view of differential expression of proteins in blood or tissue. Ultimately, this may lead to the distinction of disease phenotypes, which has a growing importance in cancer research, where the personalized treatment of patients offer more sufficient targeted therapy, and thus can ease the burden of healthcare.
Tissue samples, well characterized by pathologist, are particularly useful subjects for such comparative proteomic analyses, which may reveal new insights to the heterogeneity of diseases like cancer. Our research experiences indicate that deep proteomic analyses of these clinically valuable samples require thorough preparation procedures, which are currently a major focus of developments. Novel and effective preparation methods in combination with archived biobanking material, such as formalin-fixed and paraffin-embedded tissues, will be beneficial for future improvements .
Lastly, we would like to express our appreciation to the authors of this Special Issue for their contributions and the staff of International Journal of Proteomics for their meticulous handling of the articles. We strongly hope that the readers this Special Issue can provide novel and stimulating data and views of clinical proteomics.
John G. Marshall
- R. Apweiler, C. Aslanidis, T. Deufel et al., “Approaching clinical proteomics: current state and future fields of application in fluid proteomics,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 6, pp. 724–744, 2009.
- L. Anderon, “Candidate-based proteomics in the search for biomarkers of cardiovascular disease,” Journal of Physiology, vol. 563, no. 1, pp. 23–60, 2005.
- A. M. Hawkridge and D. C. Muddiman, “Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality,” Annual Review of Analytical Chemistry, vol. 2, pp. 265–277, 2009.
- O. Azimzadeh, Z. Barjaktarovic, M. Aubele et al., “Formalin-fixed paraffin-embedded (FFPE) proteome analysis using gel-free and gel-based proteomics,” Journal of Proteome Research, vol. 9, no. 9, pp. 4710–4720, 2010.